STOCK TITAN

Merit Medical Launches the Micro ACE™ Advanced Micro-Access System

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Merit Medical Systems, Inc. announces the commercial release of its FDA-cleared Micro ACE Advanced Micro-Access System, designed to achieve successful micro-access in challenging cases. The system offers improved stiffness and resiliency over competitors, enhancing visibility and accuracy during interventional procedures.
Positive
  • Merit Medical Systems, Inc. launches the FDA-cleared Micro ACE Advanced Micro-Access System.
  • The system combines stiffness and resiliency for successful micro-access in challenging cases.
  • Micro ACE offers twice the resistance to kink and compression compared to competitors.
  • The system is 9% stiffer than the leading standard micro-introducer.
  • Unique marker tip design provides nine times greater visibility under fluoroscopy for accurate positioning.
  • Merit is seeking patents for Micro ACE technology in the United States and internationally.
Negative
  • None.

The release of Merit Medical Systems' Micro ACE Advanced Micro-Access System represents a significant development in the field of vascular intervention technology. The device's enhanced stiffness and resiliency could offer a substantial improvement over existing micro-access solutions, potentially leading to better patient outcomes in procedures related to atherosclerosis. The fact that the Micro ACE provides twice the resistance to kink and compression compared to its leading competitor, coupled with a 9% increase in stiffness, suggests that it could become the new standard for such procedures, assuming clinical results support the initial claims.

From an investment perspective, Merit's pursuit of international and domestic patents for the Micro ACE technology indicates a strategic move to solidify its market position and protect its intellectual property, which could have a positive effect on the company's long-term valuation. However, the impact on the company's financials will depend on the adoption rate of the Micro ACE system by healthcare providers and the success in obtaining the CE mark designation for the European market.

The commercial release of FDA-cleared devices like Merit's Micro ACE system is often a catalyst for stock market movement, as it directly affects a company's product line and market share. The introduction of this device into Merit's Vascular portfolio expands the company's offerings in a market where technological advancements are critical for maintaining competitive edge. The emphasis on the device's visibility under fluoroscopy addresses a key operational challenge in vascular procedures, which is precise positioning. This feature alone could drive preference among interventional radiologists and cardiologists.

Long-term, the success of Micro ACE in the market will hinge on its clinical efficacy and cost-effectiveness compared to alternative devices. If the system delivers on its promises, it could lead to increased sales and market penetration for Merit Medical Systems, positively influencing its stock performance. Investors will closely monitor post-market studies and adoption rates to gauge the potential financial impact.

Merit's Micro ACE system directly addresses the challenges faced in micro-access procedures by offering a product that combines the necessary stiffness for ease of insertion with the flexibility to navigate complex vascular anatomies. The increased visibility under fluoroscopy due to the unique marker tip design is a significant advancement, as it aids in the precision required during these delicate procedures. The clinical implications of this could be profound, potentially reducing procedure times and improving outcomes.

As a specialist in the field, the ability to use a device that resists kinking and compression is invaluable. It minimizes the risk of procedural complications, such as vessel damage or suboptimal device placement. If the Micro ACE system delivers on its design promises in real-world settings, it could become a preferred tool for interventional radiologists and could set a new standard for micro-access devices in the industry.

Micro ACE combines a unique balance of stiffness and resiliency to achieve successful micro-access in challenging cases

SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System. Merit also intends to file Micro ACE for CE mark designation.

The Micro ACE system is the latest innovation in the Merit Vascular portfolio. The comprehensive portfolio includes a full range of percutaneous access and closure devices. Combining a balance of stiffness and resiliency, Micro ACE is designed to achieve micro-access in a wide range of vascular anatomies.

Interventional procedures utilizing micro-access are commonly performed to diagnose and open narrowed (i.e., atherosclerotic) blood vessels. Atherosclerosis is an inflammatory condition that develops when there is a buildup of plaque inside the arteries. Diseases linked to atherosclerosis, such as coronary and peripheral artery disease, are the leading cause of death in the United States.1

To facilitate such interventional procedures, the Micro ACE balances stiffness and flexibility to offer twice the resistance to kink and compression over the leading competitor. 2 It is also 9% stiffer than the leading standard micro-introducer. 2 In addition, a unique marker tip design allows for nine times greater visibility under fluoroscopy for accurate positioning needed at the start of a procedure.2 Merit is pursuing patents on Micro ACE technology in the United States and internationally.

Learn more about the Micro ACE.

“Merit has always looked for opportunities to improve patient care. Micro ACE leverages our experience with reinforced sheath design to improve a procedure that is done over and over each day,” said Fred P. Lampropoulos, Merit’s Chairman and CEO. “We are excited to partner with interventional physicians to advance vascular access.”

ABOUT MERIT MEDICAL

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 700 individuals. Merit employs approximately 7,000 people worldwide.

TRADEMARKS
Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

CONTACTS 
PR/Media Inquiries 
Sarah Comstock 
Merit Medical 
+1-801-432-2864 | sarah.comstock@merit.com 

INVESTOR INQUIRIES 
Mike Piccinino, CFA, IRC 
Westwicke - ICR 
+1-443-213-0509 | mike.piccinino@westwicke.com

1. National Heart, Lung, and Blood Institute (NIH). 2022. “Atherosclerosis.” Last modified March 24, 2022. Accessed March 18, 2024. https://www.nhlbi.nih.gov/health/atherosclerosis

2. Data on File.


FAQ

What did Merit Medical Systems, Inc. announce regarding the Micro ACE system?

Merit Medical Systems, Inc. announced the commercial release of its FDA-cleared Micro ACE Advanced Micro-Access System.

How does the Micro ACE system achieve successful micro-access?

The system combines a unique balance of stiffness and resiliency.

What advantages does the Micro ACE system offer over competitors?

Micro ACE offers twice the resistance to kink and compression and is 9% stiffer than the leading standard micro-introducer.

What is the unique feature of the Micro ACE system for accurate positioning?

The unique marker tip design allows for nine times greater visibility under fluoroscopy.

What is Merit Medical Systems, Inc. doing regarding patents for the Micro ACE technology?

Merit is pursuing patents on Micro ACE technology in the United States and internationally.

Merit Medical Systems, Inc.

NASDAQ:MMSI

MMSI Rankings

MMSI Latest News

MMSI Stock Data

4.76B
56.54M
2.44%
101.72%
3.41%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SOUTH JORDAN

About MMSI

merit medical systems, inc. (nasdaq: mmsi) is a leading manufacturer of medical devices used in diagnostic & interventional cardiology & radiology procedures. its primary products consist of inflation devices used in angioplasty, stent placement & discography; diagnostic & therapeutic catheters used for various procedures in cardiology & radiology; guide wires used to place balloon angioplasty catheters within a patient's coronary arteries; products used to manage & monitor the administration of contrast & other fluid solutions during diagnostic & therapeutic procedures; thrombolytic catheters & fluid dispensing systems; angiography accessories; & standard & custom angiography kits. headquartered in south jordan, utah, a suburb of salt lake city, merit employs approximately 1,900 people worldwide. merit markets its products in the united states & europe (direct sales force) & the world (distributors). they call directly on physicians & clinicians in hospitals & clinics worldwide. the c